Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
Mesti Tanja, Bouchemal Nadia, Banissi Claire and 7 more
Radiology and Oncology · 2018
doi:10.2478/raon-2018-0046 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Malignant gliomas are rapidly growing tumours that extensively invade the brain and have bad prognosis. Our study was performed to assess the metabolic effects of bevacizumab on the glioma cells carrying the IDH1 mutation, a mutation, associated with better prognosis and treatment outcome. Bevacizumab is known to inhibit tumour growth by neutralizing the biological activity of vascular endothelial growth factor (VEGF). However, the direct effects of bevacizumab on tumour cells metabolism remain poorly known.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.